This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Poster presentation

Therapeutic drug monitoring of new formulation Kaletra in pregnancy

V Jackson¹, LJ Else², SH Khoo², SE Gibbons², M Brennan¹, EO Connor³, N Boyle⁴, C Fleming⁴, S Coulter-Smith¹ and J Lambert⁵

¹The Rotunda Hospital, Dublin, Ireland

²Department of Pharmacology, University of Liverpool, Liverpool, UK

³The Mater Misericordiae University Hospital, Dublin, Ireland

⁴University College Hospital Galway, Galway, Ireland

⁵The Rotunda Hospital, The Mater Misericordiae University Hospital and University College Dublin, Dublin, Ireland

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):P199doi:10.1186/1758-2652-11-S1-P199

Published:	10 November 2008

First paragraph (this article has no abstract)

The new LPV/r tablet formulation has significant patient benefits over the old LPV/r SGC, including a lack of food/fluid restrictions, no need for refrigeration and a reduced daily pill count. However, like many antiretroviral drugs, the pharmacokinetics of the new LPV/r tablet during pregnancy is poorly understood. Here we report total and unbound LPV plasma concentrations during pregnancy and at post-partum.